Emlenoflast sodium

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target:	HY-137245A 2380032-29-9 C ₁₉ H ₂₃ N ₄ NaO ₃ S 410.47 NOD-like Receptor (NLR)	
Pathway:	Immunology/Inflammation	O´ ∖\
Storage:	 -20°C, sealed storage, away from moisture * The compound is unstable in solutions, freshly prepared is recommended. 	\succ

SOLVENT & SOLUBILITY

In Vitro	DMSO : 240 mg/mL (5	DMSO : 240 mg/mL (584.70 mM; Need ultrasonic)					
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.4362 mL	12.1812 mL	24.3623 mL		
		5 mM	0.4872 mL	2.4362 mL	4.8725 mL		
		10 mM	0.2436 mL	1.2181 mL	2.4362 mL		
	Please refer to the so	lubility information to select the app	propriate solvent.				
In Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6 mg/mL (14.62 mM); Clear solution					
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 6 mg/mL (14.62 mM); Clear solution					
		3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 6 mg/mL (14.62 mM); Clear solution					

BIOLOGICAL ACTIVITY		
DIOLOGICALACITY		
Description	Emlenoflast (MCC7840) sodium, a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC ₅₀ of <100 nM. Emlenoflast sodium can be used for the research of inflammatory diseases ^{[1][2]} .	
IC₅₀ & Target	NLRP3 inflammasome <100 nM (IC ₅₀)	
In Vitro	Emlenoflast, a MCC950 analogue, shows useful activity in the inhibition of activation of the NLRP3 inflammasome, with an IC ₅₀ of <100 nM ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

www.MedChemExpress.com

Product Data Sheet

In Vivo	?Emlenoflast (20 mg/k	Emlenoflast (4 mg/kg; i.v.) exhibits the half-life (3.39 h), AUC _{0-last} (107097 ng?h/mL) and CL (0.621 mL/min/kg) in mice ^[2] . ?Emlenoflast (20 mg/kg; p.o.) exhibits the oral bioavailability (67.2%), C _{max} (60467 ng/mL) and half-life (5.02 h) in mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Male C57BL/6 mice (7-9 weeks) ^[2]		
	Dosage:	4 mg/kg for i.v. and 20 mg/kg for p.o. (Pharmacokinetic Analysis)		
	Administration:	A single intravenousbolus or oral gavage		
	Result:	I.v.: t _{1/2} =3.39 h; AUC _{0-last} =107097 ng•h/mL; CL=0.621 mL/min/kg. P.o.: F=67.2%; C _{max} =60467 ng/mL; t _{1/2} =5.02 h.		

REFERENCES

[1]. El-Sharkawy LY, et, al. Inhibiting the NLRP3 Inflammasome. Molecules. 2020 Nov 25;25(23):5533.

[2]. O'neill L, et, al. Sulfonylureas and related compounds and use of same. WO2016131098A1.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA